Spero Therapeutics (SPRO) Non Operating Investment Income (2019)
Spero Therapeutics' (SPRO) quarterly Non Operating Investment Income came in at -$6000.0 in Q1 2019.
Spero Therapeutics (SPRO) Non Operating Investment Income (2019) Analysis & Trends
Spero Therapeutics (SPRO) has 1 years of Non Operating Investment Income data on file, last reported at -$6000.0 in Q1 2019.
- Quarterly Non Operating Investment Income changed N/A year-over-year to -$6000.0 in Q1 2019, while the trailing twelve-month figure through Dec 2019 was -$6000.0 (changed N/A YoY) and the FY2019 annual result came in at -$6000.0, changed N/A from the prior year.
- Non Operating Investment Income held at -$6000.0 in Q1 2019.
- In the past five years, Non Operating Investment Income ranged from a high of -$6000.0 in Q1 2019 to a low of -$6000.0 in Q1 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Spero Therapeutics | 70.72 Mn | 19.95 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2019 | -6,000.00 |
| Mar 31, 2019 | -6,000.00 |